Skip to Content
Interactive Textbook on Clinical Symptom Research Logo

Home Button

Hot Flashes Study Sections
 Author Bio
Introduction 
Commentator Bio
Protocol Schema
Protocol Background
Protocol Goals
Patient Eligibility
Test Schedule
Stratification Factors
Registration/Randomization
Protocol Treatment
Dosage Modification
Currently selected section: Ancillary Treatment
Toxicity Monitoring
Treatment Evaluation
Descriptive Factors
Treatment/Follow-up
Pharmacologic Studies
Drug Information
Statistical Considerations
Pathology Considerations
Records/Data Collection Procedures
Budget
Appendices

 

Chapter 2B: Development of a Clinical Trial for Hot Flash Protocol: Ancillary Treatment
  

Microphone Image

9.0 All ancillary treatments, as appropriate for symptom control and cancer therapy, may be administered as clinically indicated with the exception of treatment for hot flashes. Although, at the time of study entry, patients with current or planned therapy with antineoplastic chemotherapy, androgens, estrogens, progestational agents, or corticosteroids are not eligible for this study. If, during the conduct of this study, any of these agents become clinically appropriate, they may then be given (record reason clearly on the Nurse Work Sheet, comment section (Appendix V or Appendix VII). If these agents need to be administered, the patient will be excluded from the primary analysis as of that date.


Page 16 of 29